Cover Image
市場調查報告書

Lampalizumab (黃斑部水腫·黃斑部病變) :預測·市場分析

Lampalizumab (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 325958
出版日期 內容資訊 英文 109 Pages
訂單完成後即時交付
價格
Back to Top
Lampalizumab (黃斑部水腫·黃斑部病變) :預測·市場分析 Lampalizumab (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023
出版日期: 2014年10月31日 內容資訊: 英文 109 Pages
簡介

Lampalizumab是以補體因子D為標鞄的人體化單株抗體 (人mAb) 之抗原結合性片段。

本報告提供全球黃斑部水腫·黃斑部病變市場相關調查,提供您包含流行病學,病因,症狀,診斷,病理學,及治療指南的黃斑部水腫·黃斑部病變概要,以及包含競爭情形概要,產品說明,安全性,及功效簡介等的Lampalizumab詳細資訊,並彙整主要國家(美國·法國·德國·義大利·西班牙·英國·日本)的銷售額預測,銷售額資訊等資料。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 黃斑部病變概要
    • 病因·病理學
    • 分類
    • 症狀·診斷
  • 黃斑部水腫概要

第4章 疾病管理

  • 診斷·治療概要
    • 黃斑部水腫的診斷
    • 黃斑部病變的診斷
    • 治療指南·主要的處方藥
    • 臨床診療

第5章 競爭評估

  • 概要

第6章 未滿足需求·機會

  • 概要
  • 乾燥型AMD (乾燥型老年性黃斑部病變) 的治療
    • 未滿足需求
    • 差距分析
    • 機會
  • 長效型抗VEGF治療藥療法
  • 擴大滲出型AMD (滲出型老年性黃斑部病變) 用抗VEGF治療的功效
  • 低侵入性製劑
  • 認識·初期的患者診斷
  • AMD家庭監測的發展

第7章 開發平台評估

  • 概要
  • 臨床開發的潛力藥劑

第8章 Lampalizumab

  • 概要
  • 功效
  • 安全性
  • 投藥·處方
  • 臨床·商業定位的可能性
  • SWOT分析
  • 預測

第9章 附錄

  • 參考文獻
  • 簡稱
  • 調查手法
  • 預測手法
  • 一次調查:KOL採訪
  • 一次調查:亂髮處方籤的醫生調查
  • 關於作者
  • 關於GlobalData
  • 免責聲明

圖表清單

目錄
Product Code: GDHC488DFR

Macular Edema is a condition where fluid accumulates on the macula, leading to vision impairment or in severe cases even vision loss. The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or branch retinal vein occlusion (ME-CRVO and ME-BRVO). Age-related macular degeneration (AMD) is a painless eye condition which leads to gradual, irreversible, loss of central vision, and is one of the leading causes of blindness among people aged 50 and over in the developed world. Currently the ME and AMD markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector. The AMD market will see the arrival of the first therapies to treat dry AMD, fulfilling a huge unmet need in the management of this retinal disease, and these first-in-class therapies will strongly drive the market growth over the next ten years. The launch of wet AMD adjunctive therapies will also see a significant change in the treatment of AMD patients and have a positive impact on the market growth.

Lampalizumab, also known as anti-factor D (as well as RG7417 by Roche and as FCFD4514S by its subsidiary, Genentech), is an antigen-binding fragment of a humanized mAb that targets complement factor D, the rate-limiting enzyme involved in the activation of the alternative complement pathway.

Scope

  • Overview of Macular Edema and Macular Degeneration, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Lampalizumab including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Lampalizumab for the top country from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, UK and Japan

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return.
  • Stay ahead of the competition by understanding the changing competitive landscape for Macular Edema and Macular Degeneration.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
  • Make more informed business decisions from insightful and in-depth analysis of Lampalizumab performance.
  • Obtain sales forecast for Lampalizumab from 2013-2023 in top 7 countries (the US, France, Germany, Italy, Spain, UK and Japan).

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Related Reports

3. Disease Overview

  • 3.1. Macular Degeneration Overview
    • 3.1.1. Etiology and Pathophysiology
    • 3.1.2. Classification
    • 3.1.3. Symptoms and Diagnosis
  • 3.2. Macular Edema Overview
    • 3.2.1. Etiology and Pathophysiology
    • 3.2.2. Classification
    • 3.2.3. Symptoms and Diagnosis

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Macular Edema Diagnosis
    • 4.1.2. Macular Degeneration Diagnosis
    • 4.1.3. Treatment Guidelines and Leading Prescribed Drugs
    • 4.1.4. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. Treatment for Dry AMD
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Longer-Acting Anti-VEGF Drug Therapy
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Increased Efficacy of Anti-VEGF Therapy for wAMD
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Less Invasive Drug Formulations
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity
  • 6.6. Awareness and Earlier Patient Diagnosis
    • 6.6.1. Unmet Need
    • 6.6.2. Gap Analysis
    • 6.6.3. Opportunity
  • 6.7. Home Monitoring of AMD Progression
    • 6.7.1. Unmet Need
    • 6.7.2. Gap Analysis
    • 6.7.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development

8. Lampalizumab

  • 8.1. Overview
  • 8.2. Efficacy
  • 8.3. Safety
  • 8.4. Dosing and Formulation
  • 8.5. Potential Clinical and Commercial Positioning

8.6. SWOT Analysis

  • 8.7. Forecast

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed ME and AMD Patients
    • 9.4.2. Percentage of Drug-Treated Patients
    • 9.4.3. General Pricing Assumptions
    • 9.4.4. Pricing of Pipeline Agents
  • 9.5. Primary Research - KOLs Interviewed for this Report
  • 9.6. Primary Research - High-Prescribers Survey
  • 9.7. About the Authors
    • 9.7.1. Analyst
    • 9.7.2. Therapy Area Director
    • 9.7.3. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Disclaimer

List of Tables

  • Table 1: ARM System Classification of AMD
  • Table 2: Symptoms of AMD
  • Table 3: National and International Treatment Guidelines for ME and AMD
  • Table 4: Most Prescribed Drugs for ME and AMD in the Global Markets, 2013
  • Table 5: Leading Treatments for ME and AMD, 2014
  • Table 6: Unmet Needs and Opportunities in ME and AMD
  • Table 7: Promising Drugs in Clinical Development for ME and AMD
  • Table 8: Comparison of Drugs in Development for ME and AMD, 2014
  • Table 9: Product Profile - Lampalizumab
  • Table 10: SWOT Analysis - Lampalizumab, 2014
  • Table 11: Global Sales Forecast ($m) for lampalizumab, 2013-2023
  • Table 12: Surveyed High-Prescribing Physicians (Non-KOLs), by Country

List of Figures

  • Figure 1: Anatomy of the Eye and Macula
  • Figure 2: Amsler Grid viewed by Patient with Normal Vision and with wAMD
  • Figure 3: Color Fundus Photographs of Dry and Wet AMD
  • Figure 4: FAF Imaging of GA
  • Figure 5: Imaging of wAMD
  • Figure 6: CMT in DME
  • Figure 7: RVOs (BRVO and CRVO) on an FA
  • Figure 8: Increased CRT in ME-RVO
  • Figure 9: ME Clinical Treatment Flowchart
  • Figure 10: AMD Clinical Treatment Flowchart
  • Figure 11: Competitive Assessment of Late-Stage Pipeline Agents in ME and AMD, 2013-2023
  • Figure 12: Lampalizumab's Development in wAMD
  • Figure 13: Clinical and Commercial Positioning of lampalizumab
Back to Top